Split History
ETFs Holding AIMT »    AIMT Historical Stock Prices »
Video: What is a Stock Split?

If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Aimmune Therapeutics is a clinical-stage biopharmaceutical company focusing on therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. Co.'s therapeutic approach, Characterized Oral Desensitization ImmunoTherapy (CODITTM), is designed to desensitize patients to food allergens and thereby reduce the risk of having an allergic reaction upon accidental exposure, or reduce symptom severity should an allergic reaction occur. Co.'s primary CODIT product candidate, AR101, is an investigational biologic for the treatment of patients 4-17 years of age with peanut allergy. According to our AIMT split history records, Aimmune Therapeutics has had 1 split.
AIMT split history picture
Aimmune Therapeutics (AIMT) has 1 split in our AIMT split history database. The split for AIMT took place on November 17, 2004. This was a 5 for 1 split, meaning for each share of AIMT owned pre-split, the shareholder now owned 5 shares. For example, a 1000 share position pre-split, became a 5000 share position following the split.

When a company such as Aimmune Therapeutics splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business. Looking at the AIMT split history from start to finish, an original position size of 1000 shares would have turned into 5000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Aimmune Therapeutics shares, starting with a $10,000 purchase of AIMT, presented on a split-history-adjusted basis factoring in the complete AIMT split history. AIMT split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 08/06/2015
End date: 07/19/2019
Start price/share: $24.10
End price/share: $18.34
Dividends collected/share: $0.00
Total return: -23.90%
Average Annual Total Return: -6.68%
Starting investment: $10,000.00
Ending investment: $7,608.47
Years: 3.95
Date Ratio
11/17/20045 for 1
AIMT is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

AIQ Split History
AIRM Split History
AKER Split History
ALBO Split History
ALC Split History
ALKS Split History
ALPN Split History
ALQA Split History
ALR Split History
ALT Split History

Also explore: AIMT shares outstanding history

Neuralstem, Inc. (CUR)
Francesca's Holdings Corporation (FRAN)
China Green Agriculture, Inc. (CGA)
Xenetic Biosciences, Inc. (XBIO)
Yuma Energy, Inc. (YUMA)
Avinger, Inc. (AVGR)
Sonoma Pharmaceuticals, Inc. (SOMA)
Hudson Global, Inc. (HSON)
Jaguar Health, Inc. (JAGX)
Cesca Therapeutics Inc. (KOOL)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

AIMT Insider Buying

AIMT Split History | www.SplitHistory.com | Copyright © 2013 - 2019, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.